Scientists from the Tokyo Institute of Technology, Tokyo Medical University, and Saitama Medical University have published findings that offer insights into how the drug pomalidomide benefits some patients with a cancer called multiple myeloma. Clinicians use pomalidomide to treat cases of multiple myeloma resistant to the more established drug lenalidomide, and the research team found that pomalidomide...
